Our ScienceMEASURING FUNCTIONAL TUMOR BIOLOGY FOR CLINICAL DECISION SUPPORT
Cancer care is built on events—biopsies, imaging, pathology, and treatment decisions.
But cancer biology changes long before those events occur.
Hessian Labs has spent three decades advancing the science of platelet biology and discovering how platelets selectively sequester proteins that reflect active disease processes.
That work led to ClariaIQ™—the first platelet proteomics platform designed to measure functional tumor biology directly and create a new biological information layer for clinical decision support.
ClariaIQ™: The First Platelet Proteomics Platform for biology-first medicine
ClariaIQ™ is Hessian Labs’ proprietary molecular informatics platform, built on breakthrough discoveries in platelet biology. It transforms platelet protein signals into organ- and disease-specific diagnostics with exceptional precision.
Genes reveal what could happen. Proteins reveal what is happening now.
By analyzing platelet protein content, ClariaIQ captures the active biological programs that drive cancer progression, therapeutic response, and disease behavior.
Because platelets continuously sequester proteins from the tumor microenvironment, they provide a dynamic and enriched view of real-time disease biology—often before structural changes appear on imaging or traditional molecular signals emerge.
ClariaIQ translates these complex biological signals into clinically actionable insights that extend beyond static DNA mutation analysis, enabling earlier detection, more precise risk stratification, treatment monitoring, and better clinical decision support.
ClariaIQ-powered HeLP™ diagnostics are advancing in prostate and breast cancer, with additional applications in pancreatic cancer and neurodegenerative disease in development.
why current diagnostics miss active disease biology
Most cancer diagnostics measure structure, mutation, or disease presence—but not biological behavior.
Imaging shows where disease is. Genomics reveals mutations that may influence risk. Pathology describes what tissue looks like.
But none of these fully explain what the cancer is actively doing right now.
Cancer progression is driven by dynamic biological programs—angiogenesis, immune evasion, invasion, proliferation, and therapeutic resistance. These programs determine whether disease is aggressive or dormant, responding or escaping treatment.
A mutation does not always mean a pathway is active. A clear scan does not always mean disease is gone.
That gap creates uncertainty in clinical care.
Platelet proteomics closes that gap.
Because platelets continuously sequester proteins from the tumor microenvironment, they capture the active biology of disease in real time. This enables earlier detection of relapse, clearer understanding of treatment response, and more precise clinical decision support.
This is the foundation of true precision oncology—not simply finding cancer, but understanding its behavior.
The DifferencePlatelet Biology: a new Window into cancer
Hessian Labs is pioneering platelet proteomics for next-generation cancer diagnostics.
While genomic assays provide the static blueprint of disease, proteins reflect what is happening in real time—continuously shaped by the host, the tumor microenvironment, and the biological programs driving progression.
This makes proteins the most dynamic and clinically relevant measure of tumor behavior.
Platelets act as the body’s natural biological sensors, selectively sequestering proteins from tissues and concentrating signals that reflect active disease processes. These platelet-associated proteins provide an enriched view of cancer biology—capturing angiogenesis, immune signaling, invasion, therapeutic response, and disease progression.
By decoding these protein signatures, Hessian identifies organ-specific biological programs, detects clinically significant cancers earlier, and provides clearer clinical decision support throughout diagnosis, treatment, and monitoring.